Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01, Zacks reports. Dr. Reddy's Laboratories had a net margin of 17.81% and a return on equity of 18.53%.
Dr. Reddy's Laboratories Stock Down 1.0 %
NYSE RDY traded down $0.14 on Friday, reaching $14.02. The company had a trading volume of 1,781,386 shares, compared to its average volume of 2,268,659. The firm has a 50-day moving average of $14.86 and a 200-day moving average of $15.52. Dr. Reddy's Laboratories has a 1 year low of $13.61 and a 1 year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. The firm has a market capitalization of $11.70 billion, a PE ratio of 22.39 and a beta of 0.51.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on RDY. StockNews.com cut Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Nomura downgraded Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. Finally, Barclays decreased their target price on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th.
View Our Latest Stock Analysis on RDY
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Stories
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
